Who are Commercial Formulation Etanercept's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Biological: Etanercept and its biosimilars, Etanercept via Autoinjector A, Yisaipu®, Etanercept (ENBREL®), etanercept (EnbrelTM), Etanercept via Autoinjector B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/commercial-formulation-etanercept.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Commercial Formulation Etanercept — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Commercial Formulation Etanercept (Commercial Formulation Etanercept) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF receptor antagonist. Area: Immunology.

phase 3 TNF receptor antagonist TNF-α and TNF-β Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Commercial Formulation Etanercept (Commercial Formulation Etanercept) — Amgen. Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Commercial Formulation Etanercept TARGET	Commercial Formulation Etanercept	Amgen	phase 3	TNF receptor antagonist	TNF-α and TNF-β
Biological: Etanercept and its biosimilars	Biological: Etanercept and its biosimilars	Hanyang University Seoul Hospital	marketed	TNF receptor antagonist / TNF inhibitor	TNF-α and TNF-β
Etanercept via Autoinjector A	Etanercept via Autoinjector A	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β
Yisaipu®	Yisaipu®	Nanfang Hospital, Southern Medical University	marketed	TNF receptor antagonist	TNF-α and TNF-β
Etanercept (ENBREL®)	Etanercept (ENBREL®)	Amgen	marketed	TNF receptor antagonist	TNF-α and TNF-β
etanercept (EnbrelTM)	etanercept (EnbrelTM)	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	TNF receptor antagonist (TNF inhibitor)	TNF-α and TNF-β (tumor necrosis factor)
Etanercept via Autoinjector B	Etanercept via Autoinjector B	Amgen	marketed	TNF inhibitor (TNF receptor fusion protein)	TNF-α and TNF-β

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF receptor antagonist class)

Amgen · 3 drugs in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Commercial Formulation Etanercept — Competitive Intelligence Brief. https://druglandscape.com/ci/commercial-formulation-etanercept. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab